Lactam Derivative Multi-Receptor Binding for Schizophrenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic medications for schizophrenia have limitations, including significant side effects such as extrapyramidal symptoms, tardive dyskinesia, weight gain, and QT interval prolongation, while offering varying degrees of effectiveness for positive and negative symptoms.
Innovation Solution
A lactam compound derivative with a specific chemical structure that binds to multiple receptors, including D2, 5-HT1A, 5-HT2A, and 5-HT7, reducing side effects and improving cognitive disorders, formulated into a pharmaceutical composition for oral, parenteral, or topical administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If typical anti-schizophrenia drugs (e.g., chloropromazine and haloperidol) block dopamine D2 receptor, then therapeutic effect on positive symptoms is improved, but side effects like extrapyramidal system reaction, tardive dyskinesia and increase of prolactin occur
Solution Approach 1:
The compound of formula (I) is designed to simultaneously interact with multiple receptor types (dopamine D2 receptor, 5-HT1A receptor, 5-HT2A receptor, and H1 receptor) through its multifunctional molecular structure. This multi-receptor binding capability allows the single compound to address both positive symptoms via D2 blockade and negative/cognitive symptoms via 5-HT receptor modulation, while the selective affinity profile reduces off-target side effects compared to typical antipsychotics that primarily block D2 receptors
Solution Approach 2:
The invention modifies the pharmacological parameters by adjusting the compound's affinity ratios across different receptor types. The compound exhibits high affinity for D2 receptors (Ki < 100 nM) combined with specific affinity patterns for 5-HT1A, 5-HT2A, and H1 receptors, creating an optimized receptor binding profile that achieves therapeutic efficacy while minimizing side effects such as extrapyramidal symptoms and prolactin elevation
2Reliability
If non-typical anti-schizophrenia drugs (e.g., clozapine and risperidone) block both dopamine (D2) and 5-HT2A receptors, then therapeutic effect on positive symptoms is improved and EPS side effects are reduced, but side effects of extended QT interval and hyper-prolactinemia occur
Solution Approach 1:
The compound extends the multi-receptor mechanism of non-typical antipsychotics by adding significant affinity for 5-HT1A receptors and H1 receptors to the existing D2 and 5-HT2A blockade. This expanded receptor profile addresses not only positive symptoms but also enhances treatment of negative symptoms and cognitive disorders through 5-HT1A and 5-HT7 interactions, while the balanced affinity distribution avoids the QT prolongation and hyper-prolactinemia seen with current non-typical agents
Solution Approach 2:
The invention optimizes the receptor binding parameters by achieving high affinity for D2 receptors (maintaining antipsychotic efficacy) combined with balanced affinity for 5-HT1A, 5-HT2A, and H1 receptors. This parameter optimization creates a safety profile that avoids the cardiac (QT interval) and endocrine (prolactin) side effects associated with existing non-typical antipsychotics while maintaining or improving therapeutic benefits
3Reliability
If drugs block H1 receptor during long-term medication, then bodyweight gain side effect occurs
Solution Approach 1:
The compound achieves a selective affinity profile where it maintains high affinity for D2 and 5-HT2A receptors (ensuring antipsychotic efficacy) while exhibiting low affinity for H1 receptors (minimizing bodyweight gain). This parameter differentiation in receptor binding selectivity allows the drug to provide therapeutic benefits without the metabolic side effects associated with strong H1 blockade, addressing the unmet need for weight-neutral antipsychotic treatment
Data Source
AI summary
The present invention relates to a lactam compound derivative, a medicine composition comprising the lactam compound derivative, and uses of the composition and the lactam compound derivative in preparation of a medicine for preventing or treating schizophrenia, the lactam compound derivative having a structure as shown in Formula I.